机构：[1]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[2]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China[3]Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Henan, China[4]Department of Hematology, Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China浙江大学医学院附属第一医院[5]Department of Hematology, Shengjing Hospital of China Medical University, Liaoning, China中国医科大学附属盛京医院[6]Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China[7]Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China华中科技大学同济医学院附属协和医院[8]Department of Hematology, West China Hospital of Sichuan University, Sichuan, China四川大学华西医院[9]Department of Hematology, Beijing Chao-Yang Hospital of Capital Medical University, Beijing, China北京朝阳医院[10]Department of Hematology, The Second Hospital of Hebei Medical University, Hebei, China[11]Department of Hematology, The Second Affiliated Hospital of Soochow University, Jiangsu, China苏州大学附属第二医院[12]Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei, China华中科技大学同济医学院附属同济医院[13]Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China[14]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China[15]Department of Hematology, Yuhuangding Hospital of Yantai, Shandong, China[16]Department of Hematology, The First Affiliated Hospital of Nanchang University, Jiangxi, China[17]Department of Hematology, The First Affiliated Hospital of Jilin University, Jilin, China[18]Department of Hematology, Xinjiang Uyghur Municipal People’s Hospital, Xinjiang, China[19]Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China[20]Department of Hematology, The Affiliated Hospital of Qingdao University, Shandong, China[21]Department of Hematology, The fourth Hospital of Hebei Medical University, Hebei, China河北医科大学第四医院[22]Department of Hematology, Qilu Hospital of Shandong University, Shandong, China[23]Department of Hematology, Peking University First Hospital, Beijing, China[24]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China[25]Department of Hematology, China-Japan Friendship Hospital, Beijing China[26]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangdong, China[27]Department of Hematology, Gansu Provincial Hospital, Gansu, China[28]Department of Hematology, The Third Xiangya Hospital of Central South University, Hunan, China[29]Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Anhui, China[30]Department of Hematology, Hubei, China[31]Department of Hematology, Fujian Provincial Hospital, Fujian, China[32]Department of Hematology, The Affiliated Hospital of Hebei University, Hebei, China[33]Department of Hematology, Peking University Third Hospital, Beijing, China[34]Department of Hematology, The First Hospital of China Medical University, Liaoning, China[35]Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangdong, China
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in 22 provinces of China. Fifty-four patients (7.3%) received monotherapy, 264 (36.0%) received chemoimmunotherapy, 395 (53.8%) received other combination regimens without rituximab, and 21 (2.9%) received ibrutinib. Using a multivariable Cox regression model, age > 65 years old, platelets <100 x 10(9)/L, serum albumin <3.5 g/dl, beta 2 microglobulin concentration >= 4 mg/L and LDH >= 250 IU/L predicted poor OS. In summary, our study showed that frontline treatment choices for WM are widely heterogeneous. We validated most of the established prognostic factors in the rIPSS (age >65 years, LDH >= 250 IU/L, ALB <3.5 g/dl and beta 2 microglobulin >= 4 mg/L) together with PLT <= 100 x 10(9)/L indicate a poor prognosis for patients with WM.
基金：
Beijing Natural Science Foundation [Grant
No. 7202160 to CXX], the Non-profit Central Research
Institute Fund of the Chinese Academy of Medical Sciences
[Grant No. 2019-RC-HL-001 to CXX], the CAMS Innovation
Fund for Medical Sciences [Grant No. 2016-12M-1-002 to LJ]
and the National Key Research and Development Program of
China [Grant No. 2016YFC0901503 to LJ].
第一作者机构：[1]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[2]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China[*1]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China[*2]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
推荐引用方式(GB/T 7714)：
Xin-xin Cao,Shu-hua Yi,Zhong-xing Jiang,et al.Treatment and outcome patterns of patients with Waldenstrom's macroglobulinemia: a large, multicenter retrospective review in China[J].LEUKEMIA & LYMPHOMA.2021,62(11):2657-2664.doi:10.1080/10428194.2021.1938030.
APA：
Xin-xin Cao,Shu-hua Yi,Zhong-xing Jiang,Jing-song He,Wei Yang...&Lu-gui Qiu.(2021).Treatment and outcome patterns of patients with Waldenstrom's macroglobulinemia: a large, multicenter retrospective review in China.LEUKEMIA & LYMPHOMA,62,(11)
MLA：
Xin-xin Cao,et al."Treatment and outcome patterns of patients with Waldenstrom's macroglobulinemia: a large, multicenter retrospective review in China".LEUKEMIA & LYMPHOMA 62..11(2021):2657-2664
